Telomir Pharmaceuticals, Inc. (TELO) Stock Price, Financials & Summary

Price chart

Sep 18Sep 23Sep 28Oct 1Oct 6Oct 9Oct 14Oct 19

Key dataOct 19, 2026

Open$1.04

From 52W high−37.35%

Volume29146.00

Market cap$71.53M

P/E (TTM)—

P/S (TTM)—

Div yield—

Key dataOct 19, 2026

Open

$1.04

From 52W high

−37.35%

Volume

29146.00

Market cap

$71.53M

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

−11.3x

P/E (TTM)

—

RSI (14)

35.1

MomentumView details →

1D Return

−0.95%

YTD Return

−21.43%

SummaryUpdated Jun 1, 2026

Telomir Pharmaceuticals, Inc. (NASDAQ:TELO) is a pre-clinical stage biotechnology company founded in 2021 and headquartered in Baltimore, Maryland. The company was formerly known as Metallo Therapies Inc. before changing its name in October 2022. Telomir went public in April 2019 and focuses on developing therapeutic treatments targeting human stem cells and age-related inflammatory conditions. As a pre-clinical company, Telomir has not yet generated revenue and is currently in the research and development phase of bringing its lead drug candidate to market.

Ask drillr about Telomir Pharmaceuticals, Inc. →

ValuationView details →

P/E (Fwd)

—

P/E (TTM)

—

EV/EBITDA

−11.3x

EV/Sales

—

P/S (TTM)

—

P/B (TTM)

14.2x

ProfitabilityView details →

Gross Margin

—

Net Margin

—

EBITDA Margin

—

ROE (TTM)

−116.74%

ROA (TTM)

−109.51%

Asset Turnover

0.00x

GrowthView details →

Revenue YoY

—

EPS YoY

—

FCF YoY

−55.14%

Revenue CAGR 3Y

—

EPS CAGR 3Y

+41.07%

EBITDA YoY

+63.62%

MomentumView details →

1D Return

−0.95%

YTD Return

−21.43%

1Y Return

−37.05%

RSI (14)

35.1

vs 50D SMA

−9.08%

vs 200D SMA

−15.79%

Capital & dividendView details →

Debt/Equity

0.00x

Current Ratio

16.14x

Quick Ratio

16.14x

Div Yield

—

Div Rate

—

Div Growth 1Y

—

EarningsView details →

EPS (Actual)

−$0.79

EPS Surprise

−1028.57%

Beats (12Q)

2/12

Next Q EPS Est

−$0.03

Avg Surprise (4Q)

−264.73%

Rev Surprise

—

Financials snapshotView financials →

Revenue (TTM)

0.00

Net Income (TTM)

−5.88M

Op. CF (TTM)

−4.91M

Next earningsDec 2, 2026 →

Latest newsMore news →

Telomir Pharmaceuticals, Inc. agreed to issue and sell 4,843,300 shares of common stock in a private placement at $1.16 per share for gross proceeds of approximately $5.6 million.13d ago

Billionaire entrepreneur and existing significant shareholder John Paul DeJoria increased his investment in Telomir Pharmaceuticals by an additional $1.0 million as part of the company's PIPE financing.13d ago

Similar companies

Acrivon Therapeutics, Inc. Common StockACRV Heron Therapeutics, Inc.HRTX Nutriband Inc.NTRB MediciNova, Inc.MNOV OKYO Pharma LimitedOKYO ProMIS Neurosciences, Inc.PMN Find similar companies →

Latest newsMore news →

Telomir Pharmaceuticals, Inc. agreed to issue and sell 4,843,300 shares of common stock in a private placement at $1.16 per share for gross proceeds of approximately $5.6 million.13d ago Billionaire entrepreneur and existing significant shareholder John Paul DeJoria increased his investment in Telomir Pharmaceuticals by an additional $1.0 million as part of the company's PIPE financing.13d ago Telomir Pharmaceuticals announced research findings from The Ohio State University College of Veterinary Medicine showing that Telomir-Zn inhibits cell growth in human and canine osteosarcoma models.35d ago